Hello, and thank you for standing by. Welcome to Solana Company Third Quarter Operating Results Conference Call. At this time, participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. I would now like to hand the conference over to Serena Jassy, Investor Relations. You may begin.

Before we begin, I would like to inform you that comments and responses to your questions during today's call reflect management's views as of today, November 18, 2025, only, and will include forward-looking statements and opinion statements including predictions, estimates, plans, expectations, and other similar information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued earlier today and in the sections entitled Risk Factors in our annual report on Form 10-K filed with the United States Securities and Exchange Commission or the SEC on March 25, 2025, and in other subsequent filings with the SEC. Our SEC filings can be found on our website or on the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements. We disclaim any obligation to update or revise these forward-looking statements. Please note that this conference call will be available for audio replay on our website under the news and events section of our Investor Relations page. With that, I would now like to turn the call over to Solana Company's Executive Chairman, Joseph Chi. Thank you.

Good morning, everyone, and welcome to our first earnings call since we successfully raised over $500 million to fund our digital asset treasury strategy in September. I'm Joseph Chi, the Executive Chairman of Solana Company. I'm honored and pleased to be able to work with the capable board of directors and team closely since my appointment. Additionally, since 2017, I have served as the founder and chairman of Summit Capital, one of the earliest licensed funds in Asia that invest in the crypto blockchain sector. One of the co-sponsors for the PIPE transaction and now one of two strategic advisers to Solana Company. The Solana digital edge rate digital treasury strategy and the PIPE transaction mark a new beginning for Solana Company as its shareholders. Pantera Summer is committed to providing strategic support to accelerate the growth of the company going forward. The US dollar's $120 million investment by Pantera is the single largest cash investment in Pantera history. Pantera, together with Summer Capital and its ecosystem partners, accounted for roughly half of the total capital raised, underscoring their conviction in Solana Company's strategy and long-term potential, and the company's commitment to deliver results. I believe the background experience that Pantera and Summer give HSCT both global reach and institutional credibility. Since the closing of the PIPE transaction, we are now squarely focused on executing our digital asset treasury strategy. We aim to incorporate all of the learnings from our strategic investors about what has worked well, and what hasn't worked to really hone the plan. As we look forward, there are three pillars of execution we are focused on: advocacy, capital markets, and treasury management. First, let's talk about advocacy. Our goal is to maximize shareholder value and we believe we can do so through maximizing Solana per share…

Thank you, Joseph. I'm Cosmo Jiang, a Director for Solana Company and General Partner at Pantera Capital. Pantera brings deep experience as a digital asset specialist investment firm. Pantera was the first blockchain-dedicated institutional investment firm starting in 2013. Pantera anchored the first deals that catalyzed the digital asset treasury boom earlier this year, including coining the term DAT or debt. And as such, have unmatched experience in digital asset treasuries as well as the U.S. Capital markets broadly. I will now discuss the market environment and our launch progress. Now let me take a step back. It is important to acknowledge the broader market backdrop. Over the past several months, the digital asset treasury market has cooled after a period of rapid expansion earlier in the year. That is not unexpected. From an investor's lens, when I think back to what I mapped out as the white space roughly six months ago, now in our view, much of that white space has been taken. We just witnessed the creation of a whole new category of businesses over the last seven months, and the creation of a new category can only happen once. I believe this initial genesis phase of new dApps being launched is now largely over. Now that we see the white space as largely taken, we believe the industry is entering the execution and consolidation phase. The barriers to entry are a lot higher now for new entrants. Most DATs will be outcompeted and have uninteresting outcomes, ultimately resulting in healthy industry consolidation. We at Solana Company anticipate that this will be where the strongest DATs will prove themselves out and win out through operational excellence and capital discipline. We believe the best DATs can be amazing long-term outcomes for both shareholders and token holders. Those with…

Thank you, Cosmo. At its core, the company was founded as a neurotechnology company dedicated to addressing neurologic deficits through its innovative orally applied technology platform. This proprietary platform enhances the brain's ability to activate physiologic compensatory mechanisms, promoting neuroplasticity and improving the lives of individuals with neurological conditions. The company's first commercial product, the portable neuromodulation stimulator, or PoNS, exemplifies its mission to advance neurorehab through science and technology. The company has made some exciting progress over the past quarter, both clinically and strategically. The PoNS stroke registration program study was successfully executed, resulting in positive clinical outcomes. The successful results of the stroke registrational program supported our PoNS device submission for FDA 510(k) designation filed under its current FDA breakthrough device designation. Statistical analysis for the functional gait assessment primary endpoints demonstrated PoNS' superior effectiveness in improving gait deficit by achieving a clinically meaningful mean improvement compared to the control group, reflecting the clinical significance of this therapeutic intervention. In the third quarter, we have seen increased US activity, including increased VA and cash sales. This has been supplemented by additional out-of-network third-party reimbursement. We are happy with the progress made at Healius this quarter and would like to reiterate our excitement that this strategic evolution represents Healius' next chapter as Solana Company. By aligning its corporate strategy with the Solana Foundation and the broader Solana community, Solana Company positions itself at the intersection of breakthrough neuroscience and digital asset innovation, uniting two powerful platforms for sustainable growth and technological progress. I'm excited for the future of Solana. Now I would like to turn the call over to Jeff to cover the financial results.

Thank you, Dane. Our financial results include the $500 plus million PIPE transaction that closed on September 18, 2025, and related DAT activities from that date through the end of the quarter. Our third-quarter revenue of $697,000 included first-time staking rewards income of $342,000, comprising the majority of the increase from the prior year period. For the third quarter, the cost of revenue was $103,000 compared to $187,000 for the prior year period, mainly due to decreased inventory reserve and production scrap expenses. Selling, general, and administrative expenses for 2025 were $4,600,000 compared to the $2,900,000 reported in 2024, with the increase comprised of a $101,500,000 discretionary bonus in the current year. Research and development expenses for 2025 were $900,000 compared to $1,100,000 in 2024, driven primarily by reduced clinical trial activities. Unrealized loss on digital assets of $30,500,000 resulted from the net change in fair value of digital assets held by the company as of quarter-end. Total operating expenses for 2025 were $36,000,000 compared to $3,900,000 in 2024. The resulting loss from operations for the third quarter of 2025 was $35,400,000 compared to a loss of $4,100,000 for the prior year period. The current year non-operating loss in the third quarter of $317,300,000 included a $545,700,000 loss on derivative liability attributable to the valuation of the staples warrants from the September PIPE transaction and $194,700,000 of financing costs from the September PIPE transaction, including a $171,300,000 non-cash charge from the advisory warrants issued and an $8,600,000 non-cash charge for shares issued to Clear Street, offset by a $423,300,000 gain from the change in fair value of the derivative-related derivative liability from those stapled warrants as of September 30, 2025. We reported a net loss for 2025 of $352,800,000 or a loss of $32.89 per share. We had a net loss of $3,700,000 in the prior year period or a loss of 744.35¢ per basic and diluted common share. At September 30, 2025, we had $124,000,000 in cash and $350,200,000 of digital assets at fair value for a combined total of $474,200,000. Also at that date, we had a combined total of 75,900,000 common shares and prefunded warrants outstanding. Finally, as of November 17, 2025, certain provisions of the 2025 stapled warrants related to adjustments of the Black-Scholes inputs in determining the warrant value in the event of a fundamental transaction were amended. I'll now hand it over to the operator for questions.

Thank you. Ladies and gentlemen, as a reminder to ask a question, please press 11 on your telephone, then wait for your name to be announced. To withdraw your question, please press 11 again. I'm showing no questions in the queue. I would now like to turn the call back over to Joseph for closing remarks.

Well, thank you all for joining the Solana Company third-quarter operating results update. We are pleased by the strategic change and progress we have made this quarter and look forward to sharing further updates next quarter. Thank you.

Ladies and gentlemen, that concludes today's conference call. Thank you for your participation. You may now disconnect.